Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Asset Writedowns and Impairment (2016 - 2020)

Historic Asset Writedowns and Impairment for Harvard Bioscience (HBIO) over the last 12 years, with Q4 2020 value amounting to $763000.0.

  • Harvard Bioscience's Asset Writedowns and Impairment rose 67070.71% to $763000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $767000.0, marking a year-over-year decrease of 5849.57%. This contributed to the annual value of $787000.0 for FY2020, which is 4753.33% down from last year.
  • According to the latest figures from Q4 2020, Harvard Bioscience's Asset Writedowns and Impairment is $763000.0, which was up 67070.71% from $4000.0 recorded in Q1 2020.
  • In the past 5 years, Harvard Bioscience's Asset Writedowns and Impairment ranged from a high of $941000.0 in Q2 2019 and a low of -$110000.0 during Q4 2017
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $34000.0 (2016), whereas its average is $233428.6.
  • In the last 5 years, Harvard Bioscience's Asset Writedowns and Impairment tumbled by 14054.05% in 2017 and then surged by 686000.0% in 2019.
  • Over the past 5 years, Harvard Bioscience's Asset Writedowns and Impairment (Quarter) stood at $676000.0 in 2016, then plummeted by 116.27% to -$110000.0 in 2017, then soared by 120.0% to $22000.0 in 2018, then soared by 350.0% to $99000.0 in 2019, then soared by 670.71% to $763000.0 in 2020.
  • Its Asset Writedowns and Impairment stands at $763000.0 for Q4 2020, versus $4000.0 for Q1 2020 and $99000.0 for Q4 2019.